Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)

Authors :: O'Connor, Christopher M.
Gattis, Wendy A.
Uretsky, Barry F.
Adams, Kirkwood F., Jr.
McNulty, Steven E.
Grossman, Steven H.
McKenna, William J.
Zannad, Faiez
Swedberg, Karl
Gheorghiade, Mihai
Califf, Robert M.
Source :: American Heart Journal. July, 1999, Vol. 138 Issue 1, p78, 9 p.
Publication Year :: 1999

Subjects :: Heart failure -- Complications
Dobutamine -- Health aspects
Mortality -- Risk factors
Health

Tools